Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 4, 2002, Pages 388-395

  Dore, Gregory J ^a   Li, Yueming ^a   McDonald, Ann ^a   Ree, Hugo ^a   Kaldo, John M ^a   Passaris, Irene ^a   Menzies, Robert ^a   Savage, Jan ^a   Davey, Therese ^a   Cremasco, Neil ^a   Keenan, Cathy ^a   Dowse, Gary ^a   Kaldor, John ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AIDS illnesses; Antiretroviral therapy; Australia; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DEMENTIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TUBERCULOSIS; VIRUS LOAD;

EID: 0036535112     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200204010-00010     Document Type: Article

References (36)

1. Delta. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
3. Randomised trial of addition of lamivudine or lamivudine plus loviride-zidovudine-containing regimens for patients with HIV-1 infection: The CEASAR trial
4. + cell counts of 200 per cubic millimeter or less
5. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
6. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
7. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
8. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
9. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
10. HIV disease progression in the time of combination antiretroviral therapies
11. Natural history of HIV infection in the era of combination antiretroviral therapy
12. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997
13. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997
14. Changes in AIDS defining illnesses, Royal Free Hospital 1987-1998
15. Changing patterns of disease and treatment of opportunistic parasitic infections in patients with AIDS
16. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis
17. Increasing survival time after AIDS in Italy: The role of new combination antiretroviral therapies
18. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998
19. Improving survival following AIDS in Australia, 1991-1996
20. The acquired immunodeficiency syndrome in Australia: Incidence 1982-1991
21. U.S. Centers for Disease Control and Prevention: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
22. Definition of HIV infection and AIDS-defining illness
23. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
24. Uptake of antiretroviral treatments among HIV-positive gay men
25. A Wilcoxon-type test for trend
26. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: The Australian AIDS cohort
27. AIDS across Europe, 1994-1998: The EuroSIDA study
28. Trends in the incidence of outcomes defining Acquired Immunodeficiency Syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991
29. Changing incidence of Pneumocystis carinii pneumonia as initial AIDS defining disease in the United Kingdom
30. The changing spectrum of AIDS index diseases in Canada
31. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. Coordinators for AIDS Surveillance
32. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons
33. + T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses
34. Spectrum of AIDS-defining illnesses in Australia, 1992-1998: Influence of country/region of birth
35. The role of initial AIDS-defining illness in survival following AIDS